Literature DB >> 10471573

Quantitation of intracellular triphosphate of emtricitabine in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients.

A Darque1, G Valette, F Rousseau, L H Wang, J P Sommadossi, X J Zhou.   

Abstract

An analytical methodology combining solid-phase extraction (SPE) and high-performance liquid chromatography (HPLC) was developed to quantitate the intracellular active 5'-triphosphate (TP) of beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine (emtricitabine) (FTC) in human peripheral blood mononuclear cells (PBMCs). The FTC nucleotides, including 5'-mono-, di-, and triphosphates, were successively resolved on an anion-exchange SPE cartridge by applying a gradient of potassium chloride. The FTC-TP was subsequently digested to release the parent nucleoside that was finally analyzed by HPLC with UV detection (HPLC-UV). Validation of the methodology was performed by using PBMCs from healthy donors exposed to an isotopic solution of [(3)H]FTC with known specific activity, leading to the formation of intracellular FTC-TP that was quantitated by an anion-exchange HPLC method with radioactive detection. These levels of FTC-TP served as reference values and were used to validate the data obtained by HPLC-UV. The assay had a limit of quantitation of 4. 0 pmol of FTC-TP (amount on column from approximately 10(7) cells). Intra-assay precision (coefficient of variation percentage of repeated measurement) and accuracy (percentage deviation of the nominal reference value), estimated by using quality control samples at 16.2, 60.7, and 121.5 pmol, ranged from 1.3 to 3.3% and -1.0 to 4. 8%, respectively. Interassay precision and accuracy varied from 3.0 to 10.2% and from 2.5 to 6.7%, respectively. This methodology was successfully applied to the determination of FTC-TP in PBMCs of patients infected with human immunodeficiency virus after oral administration of various dosing regimens of FTC monotherapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10471573      PMCID: PMC89455     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  A sensitive nonisotopic method for the determination of intracellular azidothymidine 5'-mono-, 5'-di-, and 5'-triphosphate.

Authors:  T Toyoshima; S Kimura; S Muramatsu; H Takahagi; K Shimada
Journal:  Anal Biochem       Date:  1991-08-01       Impact factor: 3.365

2.  Cellular pharmacology of 2',3'-didehydro-2',3'-dideoxythymidine (D4T) in human peripheral blood mononuclear cells.

Authors:  Z Zhu; H T Ho; M J Hitchcock; J P Sommadossi
Journal:  Biochem Pharmacol       Date:  1990-05-01       Impact factor: 5.858

Review 3.  The molecular biology of the hepatitis B viruses.

Authors:  D Ganem; H E Varmus
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

4.  Intracellular nucleotides of (-)-2',3'-deoxy-3'-thiacytidine in peripheral blood mononuclear cells of a patient infected with human immunodeficiency virus.

Authors:  C Solas; Y F Li; M Y Xie; J P Sommadossi; X J Zhou
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

5.  The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.

Authors:  P A Furman; M Davis; D C Liotta; M Paff; L W Frick; D J Nelson; R E Dornsife; J A Wurster; L J Wilson; J A Fyfe
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

6.  Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues.

Authors:  S L Doong; C H Tsai; R F Schinazi; D C Liotta; Y C Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

7.  Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. A phase I trial.

Authors:  G L Drusano; G J Yuen; J S Lambert; M Seidlin; R Dolin; F T Valentine
Journal:  Ann Intern Med       Date:  1992-04-01       Impact factor: 25.391

8.  A method for the quantification of intracellular zidovudine nucleotides.

Authors:  H Kuster; M Vogt; B Joos; V Nadai; R Lüthy
Journal:  J Infect Dis       Date:  1991-10       Impact factor: 5.226

9.  Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.

Authors:  R F Schinazi; A McMillan; D Cannon; R Mathis; R M Lloyd; A Peck; J P Sommadossi; M St Clair; J Wilson; P A Furman
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

10.  Intracellular metabolism of 3'-azidothymidine in isolated human peripheral blood mononuclear cells.

Authors:  Y Törnevik; B Jacobsson; S Britton; S Eriksson
Journal:  AIDS Res Hum Retroviruses       Date:  1991-09       Impact factor: 2.205

View more
  7 in total

1.  Pre-steady-state kinetic analysis of the incorporation of anti-HIV nucleotide analogs catalyzed by human X- and Y-family DNA polymerases.

Authors:  Jessica A Brown; Lindsey R Pack; Jason D Fowler; Zucai Suo
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

Review 2.  Role of Marine Natural Products in the Genesis of Antiviral Agents.

Authors:  Vedanjali Gogineni; Raymond F Schinazi; Mark T Hamann
Journal:  Chem Rev       Date:  2015-08-28       Impact factor: 60.622

Review 3.  Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.

Authors:  Peter L Anderson; Jennifer J Kiser; Edward M Gardner; Joseph E Rower; Amie Meditz; Robert M Grant
Journal:  J Antimicrob Chemother       Date:  2010-11-30       Impact factor: 5.790

4.  DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants.

Authors:  Raymond F Schinazi; John Mellors; Holly Bazmi; Sharon Diamond; Sena Garber; Karen Gallagher; Romas Geleziunas; Ron Klabe; Michael Pierce; Marlene Rayner; Jing-Tao Wu; Hangchun Zhang; Jennifer Hammond; Lee Bacheler; Douglas J Manion; Michael J Otto; Lieven Stuyver; George Trainor; Dennis C Liotta; Susan Erickson-Viitanen
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

5.  Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection.

Authors:  R G Gish; N W Y Leung; T L Wright; Huy Trinh; W Lang; H A Kessler; L Fang; L H Wang; J Delehanty; A Rigney; E Mondou; A Snow; F Rousseau
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

6.  Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia.

Authors:  Josep M Llibre; Isabel Bravo; Arelly Ornelas; José R Santos; Jordi Puig; Raquel Martin-Iguacel; Roger Paredes; Bonaventura Clotet
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

7.  Optimization (central composite design) and validation of HPLC method for investigation of emtricitabine loaded poly(lactic-co-glycolic acid) nanoparticles: in vitro drug release and in vivo pharmacokinetic studies.

Authors:  Gurinder Singh; Roopa S Pai
Journal:  ScientificWorldJournal       Date:  2014-01-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.